Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 22;11(2):371.
doi: 10.3390/diagnostics11020371.

The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer's Disease and Parkinson's Disease

Patrycja Pawlik  1 , Katarzyna Błochowiak  1
Affiliations
Review

The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer's Disease and Parkinson's Disease

Patrycja Pawlik et al. Diagnostics (Basel). .

Abstract

Many neurodegenerative diseases present with progressive neuronal degeneration, which can lead to cognitive and motor impairment. Early screening and diagnosis of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) are necessary to begin treatment before the onset of clinical symptoms and slow down the progression of the disease. Biomarkers have shown great potential as a diagnostic tool in the early diagnosis of many diseases, including AD and PD. However, screening for these biomarkers usually includes invasive, complex and expensive methods such as cerebrospinal fluid (CSF) sampling through a lumbar puncture. Researchers are continuously seeking to find a simpler and more reliable diagnostic tool that would be less invasive than CSF sampling. Saliva has been studied as a potential biological fluid that could be used in the diagnosis and early screening of neurodegenerative diseases. This review aims to provide an insight into the current literature concerning salivary biomarkers used in the diagnosis of AD and PD. The most commonly studied salivary biomarkers in AD are β-amyloid1-42/1-40 and TAU protein, as well as α-synuclein and protein deglycase (DJ-1) in PD. Studies continue to be conducted on this subject and researchers are attempting to find correlations between specific biomarkers and early clinical symptoms, which could be key in creating new treatments for patients before the onset of symptoms.

Keywords: Alzheimer’s disease; Parkinson’s disease; TAU; neurodegenerative diseases; oxidative stress; salivary biomarkers; α-synuclein; β-amyloid.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dugger B.N., Dickson D.W. Pathology of Neurodegenerative Diseases. Cold Spring Harb. Perspect. Biol. 2017;9:a028035. doi: 10.1101/cshperspect.a028035. - DOI - PMC - PubMed
    1. Farah R., Haraty H., Salame Z., Fares Y., Ojcius D.M., Said Sadier N. Salivary biomarkers for the diagnosis and monitoring of neurological diseases. Biomed. J. 2018;41:63–87. doi: 10.1016/j.bj.2018.03.004. - DOI - PMC - PubMed
    1. Liu J., Hlávka J., Hillestad R.J., Mattke S. 2020 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2020;16:391–460. doi: 10.1002/alz.12068. - DOI
    1. Hanagasi H.A., Tufekcioglu Z., Emre M. Dementia in Parkinson's disease. J. Neurol. Sci. 2017;374:26–31. doi: 10.1016/j.jns.2017.01.012. - DOI - PubMed
    1. Aarsland D., Creese B., Politis M., Chaudhuri K.R., Ffytche D.H., Weintraub D., Ballard C. Cognitive decline in Parkinson disease. Nat. Rev. Neurol. 2017;13:217–231. doi: 10.1038/nrneurol.2017.27. - DOI - PMC - PubMed